Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer

Yang, Hailei; Geng, Aizhi; Wang, Zhenfeng; Wu, Chuanzhong

doi:10.1111/jog.15644

Cited by 2 publications

(1 citation statement)

References 32 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, some PROTACs demonstrated selectivity in degrading specific HDAC isoforms, like HDAC3, exemplified by the synthesis reported by Xiao et al of an HDAC3-selective degrader exhibiting significant potency in breast cancer cells [172][173][174][175]. Moreover, several studies have investigated the PROTACmediated degradation of HDAC8 [176][177][178][179][180], highlighting its propensity for degradation alongside HDAC3 and HDAC6, with Chotitumnavee et al developing a selective HDAC8 PROTAC that outperformed its parent inhibitor in compromising cell viability [177].…”

Section: Future Perspectives and Protacsmentioning

confidence: 99%

The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods

Curcio,

Rocca,

Alcaro

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Histone deacetylases (HDACs) are crucial in gene transcription, removing acetyl groups from histones. They also influence the deacetylation of non-histone proteins, contributing to the regulation of various biological processes. Thus, HDACs play pivotal roles in various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions, highlighting their potential as therapeutic targets. This paper reviews the structure and function of the four classes of human HDACs. While four HDAC inhibitors are currently available for treating hematological malignancies, numerous others are undergoing clinical trials. However, their non-selective toxicity necessitates ongoing research into safer and more efficient class-selective or isoform-selective inhibitors. Computational methods have aided the discovery of HDAC inhibitors with the desired potency and/or selectivity. These methods include ligand-based approaches, such as scaffold hopping, pharmacophore modeling, three-dimensional quantitative structure–activity relationships, and structure-based virtual screening (molecular docking). Moreover, recent developments in the field of molecular dynamics simulations, combined with Poisson–Boltzmann/molecular mechanics generalized Born surface area techniques, have improved the prediction of ligand binding affinity. In this review, we delve into the ways in which these methods have contributed to designing and identifying HDAC inhibitors.

show abstract